Entrada Therapeutics Inc

NASDAQ:TRDA  
7.06
+0.47 (+7.13%)
Earnings Announcements

Entrada Therapeutics Reports First Quarter 2022 Financial Results

Published: 05/12/2022 11:16 GMT
Entrada Therapeutics Inc (TRDA) - Entrada Therapeutics Reports First Quarter 2022 Financial Results.
Entrada Therapeutics Inc - Cash, Cash Equivalents and Marketable Securities Were $263.9 Million As of March 31, 2022.
Entrada Therapeutics Inc - Qtrly Loss per Share $0.69.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.73

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.75

More details on our Analysts Page.